KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

NCT06767046 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal
Pancreatic
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: KRAS-specific Autologous TCR-T cell injection

Sponsor

Corregene Biotechnology Co., Ltd